INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 121 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,341 | +950.6% | 48,778 | +962.7% | 0.02% | +850.0% |
| Q1 2024 | $318 | +45.9% | 4,590 | +50.8% | 0.00% | 0.0% |
| Q4 2023 | $218 | -93.0% | 3,043 | -94.9% | 0.00% | -94.3% |
| Q3 2023 | $3,096 | +95.9% | 59,439 | +138.2% | 0.04% | +191.7% |
| Q2 2023 | $1,580 | -63.0% | 24,954 | -68.4% | 0.01% | -76.0% |
| Q1 2023 | $4,272 | +231.2% | 78,890 | +223.7% | 0.05% | +212.5% |
| Q4 2022 | $1,290 | -99.9% | 24,369 | +9.5% | 0.02% | +23.1% |
| Q3 2022 | $1,035,000 | +27.1% | 22,249 | +56.0% | 0.01% | +44.4% |
| Q2 2022 | $814,000 | +337.6% | 14,262 | +370.2% | 0.01% | +800.0% |
| Q1 2022 | $186,000 | -94.1% | 3,033 | -95.0% | 0.00% | -94.1% |
| Q4 2021 | $3,153,000 | +293.6% | 60,248 | +180.4% | 0.02% | +325.0% |
| Q3 2021 | $801,000 | -3.8% | 21,483 | +5.2% | 0.00% | 0.0% |
| Q2 2021 | $833,000 | +64.3% | 20,418 | +36.8% | 0.00% | +33.3% |
| Q1 2021 | $507,000 | -87.6% | 14,930 | -88.4% | 0.00% | -86.4% |
| Q4 2020 | $4,095,000 | +94.2% | 128,780 | +56.7% | 0.02% | +69.2% |
| Q3 2020 | $2,109,000 | +163.6% | 82,190 | +163.9% | 0.01% | +85.7% |
| Q2 2020 | $800,000 | +145.4% | 31,150 | +47.0% | 0.01% | +133.3% |
| Q1 2020 | $326,000 | -11.9% | 21,194 | +96.8% | 0.00% | 0.0% |
| Q4 2019 | $370,000 | +270.0% | 10,771 | +30.8% | 0.00% | +200.0% |
| Q1 2019 | $100,000 | -58.2% | 8,235 | -60.8% | 0.00% | -50.0% |
| Q4 2018 | $239,000 | -75.2% | 21,024 | -52.7% | 0.00% | -71.4% |
| Q3 2018 | $965,000 | +407.9% | 44,454 | +268.6% | 0.01% | +250.0% |
| Q3 2017 | $190,000 | +84.5% | 12,060 | +45.9% | 0.00% | +100.0% |
| Q2 2017 | $103,000 | -63.3% | 8,266 | -55.6% | 0.00% | -50.0% |
| Q4 2016 | $281,000 | +142.2% | 18,608 | +344.3% | 0.00% | +100.0% |
| Q1 2016 | $116,000 | -2.5% | 4,188 | +40.7% | 0.00% | 0.0% |
| Q3 2015 | $119,000 | -60.3% | 2,977 | -83.3% | 0.00% | -50.0% |
| Q2 2014 | $300,000 | – | 17,816 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |